Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | USP2 | O75604 | 2/20 | 0.72 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | MAOB | P27338 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.72 |
| ▸ | FLT3 | P36888 | 2/20 | 0.72 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.72 |
| ▸ | MAOA | P21397 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Podocarpusflavone A SCHEMBL25937932 | 1.00 | MEN1 (0.72) | MEN1KMT2AMAPTUSP2TP53 | |
| Podocarpusflavone B SCHEMBL29496271 | 0.96 | MAPT (0.73) | MEN1KMT2AMAPTUSP2TP53 | |
| Podocarpusflavone B SCHEMBL27350627 | 0.96 | MAPT (0.73) | MEN1KMT2AMAPTUSP2TP53 | |
| 7'',4'''-Dimethylamentoflavone SCHEMBL30646161 | 0.92 | APP (0.72) | MEN1KMT2AMAPTUSP2TP53 | |
| Isoginkgetin SCHEMBL22459983 | 0.92 | MEN1 (0.80) | MEN1KMT2AMAPTUSP2TP53 | |
| Isoginkgetin SCHEMBL30293900 | 0.92 | MEN1 (0.80) | MEN1KMT2AMAPTUSP2TP53 | |
| 7'',4'''-Dimethylamentoflavone SCHEMBL27350631 | 0.92 | APP (0.72) | MEN1KMT2AMAPTUSP2TP53 | |
| Sequoiaflavone SCHEMBL1158361 | 0.92 | MEN1 (0.73) | MEN1KMT2AMAPTUSP2TP53 | |
| Sequoiaflavone SCHEMBL30646160 | 0.92 | MEN1 (0.73) | MEN1KMT2AMAPTUSP2TP53 | |
| Amentoflavone SCHEMBL312563 | 0.90 | MEN1 (0.80) | MEN1KMT2AMAPTUSP2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687999-A1 | TROP2 CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS | OBI Pharma, Inc. (TW) | 2026-02-11 | — | — | EP | claimed |
| WO-2025024478-A1 | COMPOSITIONS FOR THE MODULATION OF TASTE | IXORA SCIENTIFIC INC. (US) | 2025-01-30 | — | — | WO | claimed |
| WO-2024206480-A1 | TROP2 CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS | O B I PHARMA, INC. (TW) | 2024-10-03 | — | — | WO | claimed |
| EP-4687999-A1 | TROP2 CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS | OBI Pharma, Inc. (TW) | 2026-02-11 | — | — | EP | disclosed |
| EP-4615990-A1 | GLYCOSYNTHASE VARIANTS FOR ANTIBODY-DRUG CONJUGATE ENGINEERING | OBI Pharma, Inc. (TW) | 2025-09-17 | — | — | EP | disclosed |
| US-20250228814-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF VIRAL INFECTIONS | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2025-07-17 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| WO-2025024478-A1 | COMPOSITIONS FOR THE MODULATION OF TASTE | IXORA SCIENTIFIC INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2024206480-A1 | TROP2 CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS | O B I PHARMA, INC. (TW) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024102523-A1 | GLYCOSYNTHASE VARIANTS FOR ANTIBODY-DRUG CONJUGATE ENGINEERING | OBI PHARMA, INC. (TW) | 2024-05-16 | — | — | WO | disclosed |
| WO-2023187599-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | DIDENKO KIRILL (MX) | 2023-10-05 | — | — | WO | disclosed |
| US-20230233514-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING, INC. | 2023-07-27 | — | — | US | disclosed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | disclosed |
| EP-4167984-A1 | ANTI-VIRAL COMPOUNDS AND METHODS OF USING SAME | Flagship Pioneering, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2023037254-A1 | METHODS AND COMPOUNDS FOR TREATING CORONAVIRIDAE VIRUS INFECTIONS | DIDENKO KIRILL (MX) | 2023-03-16 | — | — | WO | disclosed |
| US-20220288404-A1 | METHODS FOR APPLYING TUMOR TREATING FIELDS IN COMBINATION WITH CANCER TREATING THERAPEUTICS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-15 | — | — | US | disclosed |
| WO-2022192719-A2 | METHODS FOR APPLYING TUMOR TREATING FIELDS IN COMBINATION WITH CANCER TREATING THERAPEUTICS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-15 | — | — | WO | disclosed |
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | disclosed |
| EP-3984555-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233514-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USING THE SAME | ACE2, ACE, EIF2AK2 | MEN1 4255/4885KMT2A 2967/4885MAPT 3743/4885 |
| US-20250228814-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, MAVS | MEN1 3073/4885KMT2A 3798/4885MAPT 1798/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | MEN1 732/4885KMT2A 2058/4885MAPT 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.